Ki-67 is a prognostic marker for hormone receptor positive tumors
Clin. transl. oncol. (Print)
; 18(10): 996-1002, oct. 2016. tab, ilus, graf
Article
en En
| IBECS
| ID: ibc-155962
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Purpose: To evaluate the utility of Ki67 as a prognostic marker in Luminal B node-negative breast cancer patients. Methods: We identified 888 patients with invasive breast carcinomas who underwent surgery between 1997 and 2004. Several classical factors were collected: age, tumor size, node involvement, tumor grade, estrogen and progesterone receptors, HER2 and Ki-67 expression. We analyzed if these parameters could be considered as a prognostic factor. In early Luminal B group, we investigated which of the following biological features provide information about bad prognosis: lack of progesterone receptor expression, HER2 overexpression/amplification or high Ki-67 value. Results: The majority of patients were alive and without relapse of tumor at the moment of the analysis (70 %). The prognostic factors founded in multivariate analysis were: tumor size, node involvement, grade 3 and Ki-67 expression. When we stratified the sample by immunohistochemistry (IHC) in tumor subtypes, we assessed 680 patients and we observed 191 Luminal B tumors. The biological parameter related to the worst survival in absence of nodal involvement was Ki-67 value. Conclusions: Ki-67 represents an additional predictor of survival in Luminal B node negative breast cancer. Conversely, neither Progesterone-receptor nor HER2 status proved prognostic significance in this group in our study (AU)
RESUMEN
No disponible
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Neoplasias de la Mama
/
Antígeno Ki-67
Tipo de estudio:
Diagnostic_studies
/
Evaluation_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2016
Tipo del documento:
Article